- Conditions
- Precancerous Conditions
- Interventions
- Erlotinib & Celecoxib
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 384
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Osimertinib
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Hepatic Metastases, Colon Cancer, Rectal Cancer
- Interventions
- Bevacizumab HAI plus systemic chemotherapy, HAI plus systemic chemotherapy
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2025
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 2 more
- Conditions
- Graft vs Host Disease
- Interventions
- Pregnyl®
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 76 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Lymphoma, Non-Hodgkin, HIV Infections
- Interventions
- Filgrastim, Vincristine sulfate, Doxorubicin hydrochloride, Cyclophosphamide, Cytarabine, Dexamethasone
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 16 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1998
- U.S. locations
- 7
- States / cities
- San Francisco, California • Denver, Colorado • Boston, Massachusetts + 3 more
- Conditions
- Von Willebrand's Disorder, Healthy
- Interventions
- Not listed
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostatic Neoplasms
- Interventions
- GM-CSF, thalidomide, docetaxel
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Invasive Breast Carcinoma, Localized Estrogen Receptor-Positive Breast Carcinoma, Localized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast Carcinoma
- Interventions
- Abemaciclib, Biospecimen Collection, Imlunestrant, Questionnaire Administration, Radiologic Imaging Procedure
- Drug · Procedure · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Acute Bleeding on Long-Term Anticoagulation Therapy, Hemorrhage, Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time), Urgent Reversal of Vitamin K Antagonist (VKA) Anticoagulation
- Interventions
- 4-factor prothrombin complex concentrate (4FPCC)
- Drug
- Lead sponsor
- HealthPartners Institute
- Other
- Eligibility
- 18 Years to 125 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Cancer
- Interventions
- Topotecan, Gefitinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Sarcoma, Kaposi, HIV Infections
- Interventions
- Tumor Necrosis Factor
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 70 Years · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer
- Interventions
- M7824
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • San Francisco, California • Jacksonville, Florida + 4 more
- Conditions
- Retinitis Pigmentosa
- Interventions
- Low Dose NT-501, High Dose NT-501
- Combination Product
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 68 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 11
- States / cities
- Beverly Hills, California • Sacramento, California • San Francisco, California + 8 more
- Conditions
- Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
- Interventions
- BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide, Carboplatin, Paclitaxel, Topotecan
- Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 18
- States / cities
- Anchorage, Alaska • Los Angeles, California • Clermont, Florida + 15 more
- Conditions
- Bladder Cancer
- Interventions
- Dovitinib
- Drug
- Lead sponsor
- Noah Hahn, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • Baltimore, Maryland • Rockledge, Pennsylvania
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- TGFa-PE38 immunotoxin, conventional surgery
- Biological · Procedure
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 8
- States / cities
- Washington D.C., District of Columbia • Chicago, Illinois • Boston, Massachusetts + 5 more
- Conditions
- Lung Cancer
- Interventions
- Filgrastim, Pegfilgrastim, Etoposide, Cisplatin, radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 14
- States / cities
- Gainesville, Florida • Miami Beach, Florida • Lexington, Kentucky + 10 more
- Conditions
- Myelodysplastic Syndrome
- Interventions
- Erlotinib
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Neoplasms, Neoplasm Metastasis, Non-Small-Cell Lung Cancer
- Interventions
- EMB-01
- Drug
- Lead sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Detroit, Michigan • Canton, Ohio
- Conditions
- Factor V Leiden, Factor II, Thrombosis
- Interventions
- Not listed
- Lead sponsor
- Sequenom, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 867 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 3
- States / cities
- Grand Rapids, Michigan • Portland, Oregon • Houston, Texas
- Conditions
- Breast Neoplasms, Breast Cancer, Cancer of the Breast
- Interventions
- Lapatinib and Everolimus
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Refractory Germ Cell Tumors Expressing EGRF
- Interventions
- ZD1839 Iressa
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- BNT314, BNT327, SoC chemotherapy treatment 1, SoC chemotherapy treatment 2, Bevacizumab
- Biological · Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 482 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Grand Rapids, Michigan • Cleveland, Ohio + 1 more
- Conditions
- Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal
- Interventions
- Dasatinib, Ganitumab
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Bethesda, Maryland